Intrinsic Value of S&P & Nasdaq Contact Us

Erasca, Inc. ERAS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
48/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.60
-35%

Erasca, Inc. (ERAS) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 8 Buy, 1 Hold, 1 Sell.

The consensus price target is $11.60 (low: $5.00, high: $20.00), representing a downside of 35% from the current price $17.85.

Analysts estimate Earnings Per Share (EPS) of $-0.73 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.07 vs est $-0.73 (beat +90.5%). 2025: actual $-0.44 vs est $-0.44 (beat +0.9%). Analyst accuracy: 0%.

ERAS Stock — 12-Month Price Forecast

$11.60
▼ -35.01% Downside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Erasca, Inc., the average price target is $11.60, with a high forecast of $20.00, and a low forecast of $5.00.
The average price target represents a -35.01% change from the last price of $17.85.
Highest Price Target
$20.00
Average Price Target
$11.60
Lowest Price Target
$5.00

ERAS Analyst Ratings

Buy
10
Ratings
8 Buy
1 Hold
1 Sell
Based on 10 analysts giving stock ratings to Erasca, Inc. in the past 3 months
Rating breakdown
Buy
8 80%
Hold
1 10%
Sell
1 10%
80%
Buy
8 analysts
10%
Hold
1 analysts
10%
Sell
1 analysts

EPS Estimates — ERAS

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.07 vs Est –$0.73 ▲ 954.5% off
2025 Actual –$0.44 vs Est –$0.44 ▲ 0.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — ERAS

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message